ID: MRFR/Pharma/1037-HCR | 85 Pages | Published By Kinjoll Dey on March 2023
The bipolar disorders treatment market is anticipated to reach USD 5604.83 Million by 2030 at 3.40% CAGR during the forecast period 2022-2030
Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas are likely to dominate the global bipolar disorders and treatment market owing to technological advancement, presence of major players in the region, well-established healthcare system, and increasing cases of bipolar disorders in the region. According to the National Institute of Mental Health (NIMH), approximately 3% of adults in the US were suffering from bipolar disorders in 2016 and this percentage is expected to increase significantly in the future due to changing lifestyles. The European market is expected to be the second-largest bipolar disorders and treatment market. The market growth in this region can be attributed to the increasing number of mental disorders, increasing government funding for treatment of bipolar disorders, and growing research and development activities related to mental health. For instance, in November 2017, Mental Health UK launched a partnership with Lloyds Banking Group to help bipolar disorder patients and to manage and improve their financial and mental health. Asia-Pacific is expected to be the fastest-growing bipolar disorders and treatment market during the forecast period owing to the increasing prevalence of genetic disorders, growing awareness about bipolar disorders, and rising investment by major players in the region. According to the Black Dog Institute, bipolar disorder is related with the genetic condition of an individual, if the parents are suffering from bipolar disorder it is more than 10% likely that their children will experience the same condition in future. The Middle East & Africa is expected to account for the smallest share of the bipolar disorders treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.Bipolar disorders treatment market, by Drug Type
Bipolar disorders treatment market, by Mechanism of Action
Bipolar disorders treatment market, by End User
Bipolar disorders treatment market, by Region
Bipolar disorders treatment market, by Key Players
|Market Size||2030 :USD 5604.83 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Drug Type, Mechanism of Action and End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Allergan (Ireland), AstraZeneca (UK), Eli Lilly and Company(US), GlaxoSmithKline(UK), Abbott (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer Inc. (US), Cephalon Inc. (US), Otsuka America Pharmaceutical Inc. (US), and Gedeon Richter plc (Hungary)|
|Key Market Opportunities||side effects associated with therapy, low diagnosis rate, and dearth of experts|
|Key Market Drivers||
bipolar disorders treatment market was valued at USD 5.6 billion in 2018.
global market is expected to exhibit a strong 3.40% CAGR over the forecast period.
The growing prevalence of bipolar disorders is the major driver for the market.
The Americas and Europe dominate the global bipolar disorder treatment market.
Leading players in the market include Allergan, AstraZeneca, and Pfizer, among others.